Sai Parenteral's Limited will conduct a virtual analyst and institutional investor meeting on July 2, 2026, to discuss its business performance and outlook. The session is scheduled to take place between 10:00 AM and 11:00 AM IST and will be hosted by Axis Capital. The company has confirmed that no unpublished price sensitive information (UPSI) will be shared during the discussion.

Meeting Details

The meeting follows the disclosure requirements under Regulation 30(6) read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The event is categorized as a group meeting and will be conducted virtually.

Disclosure Constraints

The company explicitly stated that the discussions will be limited to publicly available information. Officials from Sai Parenteral's Limited will participate in the session. The schedule remains subject to change due to exigencies on the part of the host or the company. The intimation was signed by Anil Kumar Karusala, Chairman and Managing Director.

Sai Parenterals Limited has released the transcript of its earnings conference call held on May 27, 2026, detailing its operational and financial performance for the quarter and year ended March 31, 2026. The company provided guidance for financial year 2027, targeting a revenue of ₹750 crore with an EBITDA margin of 17%, driven by the execution of long-term contracts and the integration of its Australian subsidiary, Noumed Pharmaceuticals.

Financial Performance for FY26

Financial year 2026 was a transformational period for the company, marked by the acquisition of Noumed Pharmaceuticals and a successful public listing. Consolidated revenue for FY26 stood at ₹381 crore, representing a growth of 133% over the previous year. EBITDA increased to ₹47 crore, registering a growth of 18%. The consolidated figures include approximately 4.5 months of contribution from Noumed Pharmaceuticals, following its acquisition on November 12, 2025.

In the fourth quarter of FY26, which reflects the full quarter of consolidation, revenue stood at ₹198 crore with an EBITDA of ₹29 crore, representing a 15% margin. Profit after tax (PAT) for the quarter was ₹13 crore, or 6.6% of revenue. On a standalone basis, Sai Parenterals reported revenues of about ₹162 crore, a growth of 30%, with a PAT of about ₹17 crore, reflecting a growth of 64% over FY25.

Strategic Outlook and Capex Plans

The company is currently executing a growth capital expenditure program totaling ₹440 crore. This includes ₹111 crore for capacity expansion and EU-GMP upgrades at manufacturing facilities in India, and ₹18 crore for a dedicated R&D center, both funded through IPO proceeds. The acquisition included an Adelaide manufacturing facility expansion project in Australia, involving a planned investment of AUD 53 million (₹311 crore). The project has received a grant of AUD 20 million from the Federal Australian Government, with AUD 40 million invested to date.

Management stated that these ongoing capex projects are not expected to contribute to FY27 financial performance, as facilities will be commissioned towards the end of the year. The full impact of these investments is anticipated to reflect in FY28, driving margin expansion and profitability through operating leverage and vertical integration benefits.

Operational Drivers and Guidance

The company's growth strategy is built on three pillars: a rapidly growing CDMO export business, the Australia and New Zealand platform through Noumed, and a branded formulation business. During FY26, the company secured approvals for 88 dossiers across regulated and emerging markets, while Noumed added five dossiers in Q4 FY26. Additionally, 67 dossiers are under development, expected to be commercialized in FY27 and FY28.

For FY27, the company expects debt levels to peak as capex programs are completed, with a debt-to-equity ratio of approximately 0.6 times. Management emphasized that the transition towards a CDMO business model is improving working capital efficiency, and the working capital cycle is expected to improve over the coming quarters as exports increase their contribution to revenue.

The disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.